KR20120097080A - Composition comprising hedyotis diffusa extract for prevention or treatment of nonalcoholic fatty liver disease - Google Patents

Abstract

PURPOSE: A composition containing Hedyotis diffusa extract is provided to reduce ATL activation in serum and to prevent and treat nonalcoholic fatty liver diseases. CONSTITUTION: A composition for preventing and treating non-alcoholic fatty liver diseases contains 0.1-10 wt% of Hedyotis diffusa extract as an active ingredient. The extract is prepared using water or organic solvent. The nonalcoholic fatty liver disease is nonalcoholic simple steatosis, nonalcoholic steatohepatitis, or nonalcoholic cirrhosis of the liver. A health food for improving liver function contains the extract as an active ingredient. The health food includes beverages, chocolate, food, snack pizza, ramen, noodles, gum, candy, ice cream, alcoholic drinks, vitamin complexes, or health food supplements. [Reference numerals] (AA) Liver tissue neutral fat; (BB) Control group; (CC) Hedyotis diffusa group

Description

Composition Comprising Hedyotis diffusa extract for prevention or treatment of nonalcoholic fatty liver disease}

The present invention relates to a composition for the prevention or treatment of liver disease, and more particularly to a composition for the prevention or treatment of non-alcoholic fatty liver disease comprising a baekwool extract as an active ingredient.

Fatty liver disease, also called fatty liver, is a disease that causes liver damage due to abnormal accumulation of fat (triglycerides, etc.) in liver cells. The initial condition of fatty liver disease is simple fatty liver that only admits fat deposition on hepatocytes, and then it is known that the condition progresses to fatty hepatitis (including hepatic fibrosis) and liver cirrhosis or hepatocellular carcinoma. Generally, the causes of fat deposition in the liver include alcohol intake, obesity, diabetes, abnormal lipid metabolism, drugs (steroids, tetracycline, etc.), Cushing syndrome, poisoning (yellow, etc.), and high nutritional disorders. .

The causes of fatty liver disease are largely divided into alcoholic and nonalcoholic, and the liver disease caused by the former is alcoholic fatty liver disease (also called alcoholic liver injury), and the liver disease caused by the latter is nonalcoholic fatty liver disease ( It is called nonalcoholic fatty liver disease (NAFLD).

Alcoholic fatty liver disease progresses from early simple fatty liver to fatty hepatitis and cirrhosis. Although non-alcoholic fatty liver disease has been considered to remain in the simple fatty liver and the condition does not progress, it has recently been found that in non-alcoholic fatty liver disease, the condition may progress from simple fatty liver to hepatitis or cirrhosis.

Non-alcoholic fatty liver disease is characterized by fatty change, steatosis and lobular hepatitis and steatohepatitis, which are characteristic findings of alcoholic hepatitis in liver biopsy, despite the fact that there is no history of alcohol consumption that is considered to be harmful to the liver. We say case indicating). Pathological findings of the liver range from simple fatty liver (NFL) to fatty liver (Non-Alcoholic Steatohepatits, NASH), fibrosis associated with fatty hepatitis, cirrhosis, and other non-alcoholic fatty liver disease. Used to mean all.

Most of these non-alcoholic fatty liver diseases are accompanied by insulin resistance, obesity, diabetes and hyperlipidemia. If such complications exist, it is first necessary to carry out the treatment. The principle of treatment for non-alcoholic fatty liver disease is the improvement of lifestyles such as diet therapy and exercise therapy, but it is difficult to reliably implement. In non-alcoholic steatohepatitis, more aggressive drug treatment is necessary because of the high possibility of developing cirrhosis and hepatocellular carcinoma. Treatments aimed at improving oxidative stress and insulin resistance, which are considered to be important for the development and progression of non-alcoholic steatohepatitis, have also been attempted.

As described above, it is a reality that a sufficient treatment method has not been established for nonalcoholic fatty liver disease, and development of a therapeutic drug having high efficacy against nonalcoholic fatty liver disease is desired.

Meanwhile, Hedyotis diffusa is an outpost of a year-old herbaceous plant belonging to the locust family, also known as baekhwasa. Dolomite is 20 ~ 40㎝ high, with its base growing sideways, with branched branches, standing obliquely, with multicellular white hairs. The blemishes of baiyun grass are not cold or poisonous, the taste is sweet and bitter, and the active meridians are stomach, colon, small intestine, etc. ), It is effective in various types of cancers such as lung fever cough, tonsillitis, sore throat, appendicitis, dysentery, jaundice, uterine appendixitis, arthritis, and various cancers such as liver cancer, lung cancer, lymph cancer, and throat cancer. have.

The dolomite contains active substances such as anthraquinones, terpenoids, steroids, flavonoids, various organic acids and polysaccharides, and pharmacological actions include anti-cancer, anti-inflammatory, antioxidant and Neuroprotective and hepatoprotective effects are known to be excellent.

The inventors of the present invention, while sought to find a natural substance having excellent action of lowering the lipid content of liver tissue without any side effects in the living body, and tested its pharmacological effect by paying attention to the extract of the dolomite, the extract of the dolomite extract showed the ALT value in the serum. The present invention was completed by confirming that not only the reduction but also the content of triglyceride in liver tissue can be excellently prevented and treated.

Accordingly, an object of the present invention is to provide a composition capable of preventing or treating non-alcoholic fatty liver disease with excellent action of lowering lipid content of liver tissue without any side effects on the living body.

In order to achieve the object of the present invention as described above, the present invention provides a composition for the prevention or treatment of non-alcoholic fatty liver disease comprising a baiyun extract as an active ingredient.

In one embodiment of the present invention, the dolomite extract may be obtained by extraction with water or an organic solvent.

In one embodiment of the present invention, the dolomite extract can prevent or treat non-alcoholic fatty liver disease through the effect of reducing serum ALT activity.

In one embodiment of the present invention, the dolomite extract can prevent or treat non-alcoholic fatty liver disease through the effect of reducing the triglyceride content of liver tissue.

In one embodiment of the present invention, the dolomite extract may be included in 0.1 to 10% by weight based on the total weight of the composition.

In one embodiment of the present invention, the non-alcoholic fatty liver disease may be selected from the group consisting of non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, non-alcoholic cirrhosis.

In another aspect, the present invention provides a health functional food for improving liver function comprising the baekwool extract as an active ingredient.

In one embodiment of the invention, the food is selected from the group consisting of beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements Can be.

Since the extract of the present invention may decrease ALT activity in serum and also significantly reduce triglyceride content of liver tissue, the composition of the present invention comprising the same as an active ingredient may prevent or treat non-alcoholic fatty liver disease. It can be usefully used. In particular, the Dolomite grass extract is a natural substance, so it corresponds to a widely used herbal medicine, herbal composition containing the same as an active ingredient has a safe advantage even in long-term use.

Figure 1 shows the graph by measuring the ALT activity in the serum according to the input of the dolomite extract of the present invention.
Figure 2 is a graph showing the measurement of the triglyceride content of liver tissue according to the input of the dolomite extract of the present invention.

The present invention relates to a novel use of baekwool extract, characterized in that it provides a composition for the prevention or treatment of non-alcoholic fatty liver disease comprising baekwool extract as an active ingredient.

Of the present invention, baekunpul (Hedyotis diffusa ) 'is an outpost of the annual herbaceous plant belonging to the locust family. The stem is thin and round, branched from the base, and spread to the side. The stem is about 20-40 cm in length and has no hairs. Leaves are opposites, without petioles, linear, with short hairs, 1-3.5cm long butterfly, 1.5-3㎜. The lobe is triangular membranous, divided into few lobes. Flowers bloom in August-September, reddish white, hang on axillary with 2mm diameter. Calyx lobe is triangular lanceolate, 1.5 mm long. Corollas are usually 2 mm long, fruits are spherical, 3 mm in diameter, and there are four calyx lobes that are bent outwards.

The blemishes of baiyun grass are not cold or poisonous, the taste is sweet and bitter, and the active meridians are stomach, colon, small intestine, etc., and the physiological heat detoxification, Isutongrim (, 水 通淋), and vigorous redfish ), It is effective in various types of cancers such as lung fever cough, tonsillitis, sore throat, appendicitis, dysentery, jaundice, uterine appendixitis, arthritis, and various cancers such as liver cancer, lung cancer, lymph cancer, and throat cancer. have.

The components of the dolomite include anthraquinones, terpenoids, steroids, flavonoids, betulin, betulinic acid, and ursolic acid. , Oleanolic acid, stigmasterol, beta-sitosterol, beta-glycyrretinic acid, penta-coumaric acid, glu-coumaric acid, glucoside ) And Hentriacontane, and the pharmacological activity is known to exhibit anticancer activity, anti-inflammatory effect, antioxidant effect and antiviral effect.

The present invention confirms that the baekwool extract having the above characteristics reduces the serum ALT activity and also significantly reduces the triglyceride content of liver tissue, thereby preventing or preventing non-alcoholic fatty liver disease. It was first identified that it could be cured.

Therefore, the present invention can provide a composition capable of preventing or treating non-alcoholic fatty liver disease, including the baekwool extract as an active ingredient.

The dolomite extract according to the present invention may be obtained by extraction and separation from nature using extraction and separation methods known in the art, and the 'extract' as defined in the present invention may be extracted from the dolomite using an appropriate solvent. For example, it includes all the crude extract of the baiyun grass, polar solvent soluble extract or non-polar solvent soluble extract. Preferably it may be an extract extracted from the leaves of the dolomite.

As a suitable solvent for extracting the extract from the dolomite grass, any pharmaceutically acceptable organic solvent may be used, and water or an organic solvent may be used, but is not limited thereto. For example, purified water, methanol ( alcohols having 1 to 4 carbon atoms, acetone, ether, benzene, chloroform (including methanol, ethanol, propanol, isopropanol, butanol, etc.) Various solvents such as chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination. More preferably, ethanol (alcohol) can be used.

As the extraction method, any one of the methods such as hot water extraction method, cold extraction method, reflux cooling extraction method, solvent extraction method, steam distillation method, ultrasonic extraction method, elution method and compression method can be selected and used. In addition, the desired extract may be further subjected to a conventional fractionation process or may be purified using a conventional purification method. There is no limitation on the preparation method of the dolomite extract of the present invention, and any known method may be used.

For example, the dolomite extract included in the composition of the present invention may be prepared in powder form by additional processes such as distillation under reduced pressure and freeze drying or spray drying, which are extracted by the hydrothermal extraction or solvent extraction. . The primary extract may be further purified using various chromatography such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography, and the like. You can also get

Therefore, in the present invention, the dolomite extract is a concept including all the extracts, fractions and purified products obtained in each step of extraction, fractionation or purification, their dilutions, concentrates or dried products.

Looking at the method of producing a dolomite extract according to an embodiment of the present invention in more detail as follows.

In the present invention, after drying and powdered dolomite, the lower alcohol having 1 to 4 carbon atoms, preferably ethanol (alcohol), which is about 5 to 15 times the weight of the sample, is extracted for 10 to 15 hours at 20 to 25 ℃ Can be. At this time, it is preferable to use powder ground by freeze-drying the flowers or leaves as a dolomite.

The ethanol extract as described above was filtered under reduced pressure to separate the extract from the residue, and again at 20 to 25 ° C. with a lower alcohol having 1 to 4 carbon atoms, preferably ethanol (alcohol), which is about 1 to 10 times the weight of the dolomite sample. Extract for 8 hours. Next, the baiyun extract may be obtained through filtration and concentration under reduced pressure.

The composition of the present invention containing the above-mentioned Baiyun grass extract as an active ingredient may be a pharmaceutical composition or a food composition.

The pharmaceutical composition of the present invention can be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or a flavoring agent can be used.

The pharmaceutical composition may be preferably formulated into a pharmaceutical composition including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredient for administration.

Formulation forms of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include but are not limited to natural and synthetic gums such as starch, gelatin, glucose or beta-lactose, corn sweeteners, acacia, trackercance or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA can be formulated according to each disease or component, as appropriate in the art.

In one embodiment of the present invention, the dolomite extract of the present invention may be included in 0.1 to 10% by weight based on the total weight of the composition.

The composition of the present invention may also be a food composition, which may contain various flavors or natural carbohydrates as additional ingredients, as well as ordinary food compositions, in addition to containing the extract of the active ingredient, mica.

Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The aforementioned flavoring agents can advantageously be used natural flavoring agents (tautin), stevia extracts (for example rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.).

The food composition of the present invention may be formulated in the same manner as the pharmaceutical composition, used as a functional food, or added to various foods. Foods to which the composition of the present invention may be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice creams, alcoholic beverages, vitamin complexes, and health supplements. There is this.

In addition, the food composition is a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors, natural flavors and other flavors, coloring and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, in addition to the extract of baekwool grass as an active ingredient , Alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the food composition of the present invention may contain a fruit flesh for producing natural fruit juice and fruit juice beverage and vegetable beverage.

As an active ingredient of the present invention, the baekwool extract is a natural substance and has almost no toxicity and side effects, so it can be used safely even for long-term administration for the purpose of preventing or treating non-alcoholic fatty liver disease.

The present invention also provides a health functional food for improving liver function comprising the extract of Dolomite as an active ingredient.

Health functional food of the present invention can be prepared and processed in the form of tablets, capsules, powders, granules, liquid, pills and the like for the purpose of improving liver function.

In the present invention, "health functional food" refers to a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the Health Functional Food Act No. 6767, nutrients for the structure and function of the human body It is meant to be consumed for the purpose of regulating or obtaining a useful effect for health use such as physiological action.

The health functional food of the present invention may include a conventional food additive, and the suitability as a food additive, unless otherwise specified, in accordance with the General Regulations of the Food Additives and General Test Methods approved by the Food and Drug Administration, etc. Judging by the standards and standards.

Examples of the items listed in the 'Food Additive Revolution' include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark blue pigment, licorice extract, crystalline cellulose, high color pigment and guar gum; L-glutamic acid sodium preparations, noodle-added alkalis, preservative preparations, tar coloring preparations and the like.

For example, the health functional food in the form of tablets is granulated in a conventional manner by mixing the mixture of excipients, extracts, binders, disintegrants and other additives of the extract of the active ingredient of the present invention, and then compression-molded with a lubricant, etc. Alternatively, the mixture may be compression molded directly. In addition, the health functional food in the form of tablets may contain a mating agent and the like as necessary.

Hard capsules among the health functional foods in the form of capsules may be prepared by filling a mixture of the powdered baekwool extract, which is the active ingredient of the present invention, with an additive such as an excipient, in a conventional hard capsule, and the soft capsule agent contains an additive such as excipients. It can be prepared by mixing the mixture with a capsule base such as gelatin. The soft capsule agent may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.

The health functional food in the form of a cyclic form can be prepared by molding a mixture of the extract of the active ingredient of the present invention and the excipients, excipients, binders, disintegrating agents, etc. by conventionally known methods, and if necessary, the coating is carried out with sucrose or other skin Alternatively, the surface may be coated with a material such as starch or talc.

The health functional food in the form of granules can be prepared in a granular mixture of a mixture of baekwoon extract, an active ingredient of the present invention, an excipient, a binder, a disintegrant, and the like by a conventionally known method. It may contain.

Health functional foods containing the extract of the present invention as an active ingredient can significantly reduce the ALT activity in the serum and the triglyceride content of liver tissue, as confirmed in the following examples, it is effective in improving liver function.

The health functional food may be beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements.

In another aspect, the present invention provides a use of a composition comprising a baekwoon extract as an active ingredient for the manufacture of a medicament or food for the prevention or treatment of non-alcoholic fatty liver disease. The composition of the present invention comprising the above-mentioned Baiyun grass extract as an active ingredient can be used for the manufacture of a medicament or food for the prevention or treatment of non-alcoholic fatty liver disease.

In another aspect, the present invention provides a method for preventing or treating non-alcoholic fatty liver disease, comprising administering to the mammal, the baiyun extract.

As used herein, the term "mammal" refers to a mammal that is the subject of treatment, observation or experimentation, preferably humans.

As used herein, the term 'therapeutically effective amount' refers to the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as thought by a researcher, veterinarian, doctor or other clinician, Amounts that induce alleviation of the symptoms of the disease or disorder being treated. It will be apparent to those skilled in the art that the therapeutically effective dosages and frequency of administrations for the active ingredients of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered can be readily determined by one skilled in the art and includes the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, general health of the patient. It may be adjusted according to various factors including the condition, sex and diet, time of administration, route of administration and the rate of secretion of the composition, the duration of treatment, and the drugs used simultaneously. In the treatment method of the present invention, in the case of adults, the dolomite extract of the present invention is preferably administered at a dose of 1 mg / kg to 250 mg / kg once or several times a day.

In the treatment method of the present invention, the composition containing the extract of the present invention as the active ingredient is conventional through oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes. It may be administered in a phosphorous manner.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are for further illustrating the present invention, and the scope of the present invention is not limited to these examples.

< Example  1>

Dolomite  Extract manufacturer

In order to prepare a dolomite extract, first, the powder obtained by freeze-drying the dolomite leaf was extracted with a ethanol corresponding to 10 times the weight of the dolomite leaf sample for 12 hours. After extracting the extract from the residue by filtration under reduced pressure, the resultant residue was extracted for 6 hours with alcohol, which is 5 times the weight of the sample of the dolomite leaf at the beginning of extraction, and then filtered and filtered (BUCHI Labo-ratoriums Technik AG, Rotavapor RE- 111, Germany) under reduced pressure to give a dolomite ethanol extract. At this time, the yield of the dolomite ethanol extract was 12.5%.

< Example  2>

The Dolomite  Determining the Effect of Extracts on Weight

Four-week-old male C57BL / 6J-ob / ob mouse (n = 12) was purchased and after one week of acclimatization, the animals were normal control group, Baekwoon group (Battleweed grass extract) according to the egg mass method so that the average weight of each group was similar. Intake groups). The diet and drinking water were freely ingested, and the temperature and humidity of the feeding room were maintained at 20 ~ 25 ℃ and 50 ~ 60%, respectively, and the contrast was turned on and off every 12 hours. Animal weight and dietary intake were measured once a week. In addition, in relation to the statistical analysis method used here, all the results were expressed as mean ± standard deviation, and the significance test between the control group and the dolomite group was performed using the Student's t-test (α = 0.05). In addition, the control group was ingested the AIN-93G basic diet shown in Table 1 below, the experimental group was ingested for 10 weeks a diet containing 1% of the dolomite extract of the present invention obtained in Example 1 to the basic diet. After the diet was ingested in this manner, the weight of each mouse was measured to observe the change in body weight according to the ingestion of the extract of the dolomite grass, and the results are shown in Table 2 below.

AIN-93G Basic Diet Furtherance Diet (%) Corn starch ^{1 )} 39.7 Casein ^{2 )} 20.0 Luxury starch 13.2 Sucrose ^{3 )} 10.0 a-cellulose ^{4 )} 5.0 Mineral mixtures ^{5 )} 3.5 Vitamin mixtures ^{5 )} 1.0 L-cystine ^{5 )} 0.3 Choline Bitartrate ^{3 )} 0.25 4-butylhydroquinone 0.0014 Soybean oil ^{6 )} 7.0 ¹⁾ Target company, Korea
²⁾ Murry goulburn Co., Australia
³⁾ Samyangsa, Korea
⁴⁾ Sigma, USA
⁵⁾ ICN Biochemical, USA
⁶⁾ CheilJedang, Korea

Weight change in mice Weight (g) Control group 47.2 ± 1.6 Baekwoon-gun 46.7 ± 1.9

As a result, as shown in Table 2, the control group was found to be 47.2 ± 1.6 g and the Baekwoon group was found to be 46.7 ± 1.9 g, it was confirmed that there is no significant difference between the two groups.

< Example  3>

According to the invention Dolomite  Analysis of Fatty Liver Prevention and Improvement Effect

In order to verify whether the extract of the present invention prepared in Example 1 has an effect on the prevention of fatty liver and the improvement of fatty liver, serum ALT and triglyceride content of the liver tissues were measured in mice.

To this end, the experimental animals used in Example 2 were fasted for 12 hours after 11 weeks of dietary intake, and choked with carbon dioxide gas, and blood was collected from the heart with a syringe containing 10 mg of EDTA (ehylene diamine tetra acetic acid). Liver tissue was rinsed in 0.9% saline to remove the water and stored at -70 ℃ until analysis, blood was centrifuged at 3,000 × g for 15 minutes and then serum was collected and stored at -70 ℃.

<3-1> serum ALT  Active measurement

When the structure and function of the cell membrane are destroyed, ALT (Alanine aminotransferase), an enzyme widely found in the liver cytoplasm, is leaked into the blood, and the ALT level in the blood is frequently used as an indicator of liver damage.

In this experiment, ALT levels in serum were measured to verify whether the extract of the present invention is effective in preventing fatty liver and improving fatty liver.

ALT activity was measured with a quantitative kit reagent (Youngdong Pharm., Korea). 1.0 mL of ALT substrate solution was warmed for 2 minutes in a 37 ℃ water bath and then 0.2 mL of plasma was added and reacted for 30 minutes in a 37 ℃ water bath. After 30 minutes, 1.0 mL of the coloring reagent was added and left at room temperature for 20 minutes. Then, 0.4 N NaOH 10.0 mL was added and the absorbance was measured at 505 nm. ALT standard solution (2mM pyruvate) was developed for each concentration in the same manner as described above to measure the absorbance and extrapolated to a standard curve to calculate the activity of the sample.

As a result, the serum ALT activity of the control group and the dolomite group was 173.3 ± 23.4 and 146.0 ± 16.7 U / L, respectively, and the serum ALT activity of the dolomite group was significantly decreased compared to the control group (p <0.05). ). This is shown graphically in Figure 1, through which it can be inferred that the dolomite extract of the present invention has the activity of inhibiting liver damage.

<3-2> Liver tissue  Triglyceride content measurement

In this experiment, triglyceride content of liver tissue was also measured to verify whether the extract of the present invention is effective in preventing fatty liver and improving fatty liver.

The triglyceride content of liver tissue was extracted by crude fat analysis (Folch method) and measured by enzyme method. 0.1 mL of the lipid extract was taken from the heating block (Daeil tech, Korea), and then all of the solvents were dissolved in 0.2 mL of ethanol. In order to prevent turbidity with the reaction solution, 3 mL of the reaction reagent in which the enzyme reagent was dissolved was added to a buffer in which 0.5 mL of triton X-100 was added, and the reaction was measured at 550 nm for 10 minutes at 37 ° C.

As a result, the triglyceride content was 57.2 ± 8.1 mg / g liver in the hepatic tissue of the Baekwoon group compared with the control group (74.9 ± 11.7 mg / g liver). This is shown in a graph in Figure 2, through which it was confirmed that the dolomite extract of the present invention has an activity of lowering the triglyceride content in liver tissue.

In conclusion, the above-mentioned examples showed that administration of the dolomite extract of the present invention to mice can reduce serum ALT activity and lower triglyceride content in liver tissue without affecting body weight. .

So far I looked at the center of the preferred embodiment for the present invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.

Claims (8)

A composition for the prevention or treatment of non-alcoholic fatty liver disease comprising the extract of Baiyun grass as an active ingredient. The method of claim 1,
The dolomite extract is a composition for preventing or treating non-alcoholic fatty liver disease, characterized in that obtained by extraction with water or an organic solvent. The method of claim 1,
The dolomite extract is a composition for preventing or treating non-alcoholic fatty liver disease, characterized in that it has an effect of reducing serum ALT activity. The method of claim 1,
The dolomite extract is a composition for preventing or treating non-alcoholic fatty liver disease, characterized in that it has an effect of reducing the content of triglycerides of liver tissue. The method of claim 1,
The dolomite extract is a composition for the prevention or treatment of non-alcoholic fatty liver disease, characterized in that it comprises 0.1 to 10% by weight based on the total weight of the composition. The method of claim 1,
The non-alcoholic fatty liver disease is a composition for preventing or treating non-alcoholic fatty liver disease, characterized in that selected from the group consisting of non-alcoholic simple fatty liver, non-alcoholic steatohepatitis and non-alcoholic cirrhosis. Health functional food for improving liver function, including baekwool extract as an active ingredient. The method of claim 7, wherein
The food is a health functional food, characterized in that selected from the group consisting of beverages, meat, chocolate, food, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements.

Images